Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.17 USD | +3.05% | +15.67% | +64.77% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 703M |
---|---|---|---|---|---|
Net income 2024 * | -124M | Net income 2025 * | -160M | EV / Sales 2024 * | - |
Net cash position 2024 * | 86.23M | Net cash position 2025 * | 102M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.52
x | P/E ratio 2025 * |
-4.84
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.63% |
Latest transcript on Mineralys Therapeutics, Inc.
1 day | +3.05% | ||
1 week | +15.67% | ||
Current month | +15.67% | ||
1 month | +9.08% | ||
3 months | +13.63% | ||
6 months | +61.94% | ||
Current year | +64.77% |
Managers | Title | Age | Since |
---|---|---|---|
Jon Congleton
CEO | Chief Executive Officer | 60 | 20-10-31 |
Adam Levy
DFI | Director of Finance/CFO | 46 | 22-02-28 |
Jessica Ibbitson
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 21-01-31 | |
Glenn Sblendorio
BRD | Director/Board Member | 68 | 23-09-12 |
Director/Board Member | 58 | 21-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 0 M€ | +3.53% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 14.17 | +3.05% | 382,330 |
24-05-06 | 13.75 | +6.18% | 524,509 |
24-05-03 | 12.95 | -1.07% | 71,821 |
24-05-02 | 13.09 | +2.27% | 113,802 |
24-05-01 | 12.8 | +4.49% | 369,927 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.77% | 703M | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+47.07% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- MLYS Stock